On November 5, Agenus reported results for the quarter ended September 30, 2026, and achieved a net profit. It also received its first marketing authorizations for BOT+BAL and advanced preparations for the global randomized Phase 3 ROBBIN trial for colon cancer. On November 6, earnings met analyst estimates, while revenue fell short of expectations. The company’s shares declined after the results despite pipeline progress, the authorizations, and the reported new funding.
Agenus reported mixed Q3 2026 results with earnings per share meeting analyst consensus while revenues fell short, triggering a downward move in the company's stock price.
Read the full storyThe biotech firm achieved quarterly profitability and secured its first marketing authorizations for BOT+BAL while advancing preparations for the global ROBBIN trial.
Agenus outperformed Q3 analyst expectations with an $0.08 per share earnings beat while advancing its Phase 3 ROBBIN global clinical trial for colon cancer.